Bayer Pharma AG Sustainability Profile
Bayer Pharma AG, a leading global pharmaceutical company headquartered in Germany, is renowned for its innovative contributions to healthcare. Founded in 1863, Bayer has established a strong presence in major operational regions, including Europe, North America, and Asia. The company primarily focuses on prescription pharmaceuticals, consumer health products, and biotechnology, with a commitment to advancing medical science. Bayer's core offerings include treatments for cardiovascular diseases, oncology, and women's health, distinguished by their cutting-edge research and development. With a robust portfolio of unique products, Bayer has achieved significant market position, consistently ranking among the top pharmaceutical companies worldwide. Notable milestones in its history reflect a dedication to improving patient outcomes and addressing global health challenges.
DitchCarbon Score
How does Bayer Pharma AG's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Bayer Pharma AG's score of 90 is higher than 94% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Bayer Pharma AG, headquartered in Germany (DE), currently does not report specific carbon emissions data, as no emissions figures are available. However, the company is part of a broader corporate family, with emissions data and climate commitments cascaded from its parent company, Bayer Aktiengesellschaft. Bayer Aktiengesellschaft has established various climate initiatives, including Science Based Targets Initiative (SBTi) commitments and participation in the Carbon Disclosure Project (CDP). These initiatives aim to drive significant reductions in greenhouse gas emissions across their operations. While specific reduction targets for Bayer Pharma AG are not detailed, the overarching goals set by Bayer Aktiengesellschaft reflect a commitment to sustainability and climate action. As a current subsidiary of Bayer Aktiengesellschaft, Bayer Pharma AG aligns with the parent company's climate strategies, which include initiatives under the Climate Pledge and the Climate Action 100+ framework. These efforts underscore a commitment to reducing emissions and enhancing environmental responsibility within the pharmaceutical industry. In summary, while Bayer Pharma AG does not provide specific emissions data, it is integrated into a robust framework of climate commitments and initiatives inherited from Bayer Aktiengesellschaft, reflecting a dedication to addressing climate change and reducing carbon footprints.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | - | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
| Scope 2 | - | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
| Scope 3 | 1,215 | 0,000 | - | - | - | - | - | - | - | - | - | - | - | - | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
How Carbon Intensive is Bayer Pharma AG's Industry?
How Carbon Intensive is Bayer Pharma AG's Location?
Bayer Pharma AG's Scope 3 Categories Breakdown
Bayer Pharma AG's Scope 3 emissions, which decreased by 16% last year and increased significantly since 2004, demonstrating supply chain emissions tracking. Most of their carbon footprint comes from suppliers and value chain emissions, with Scope 3 emissions accounting for 72% of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 76% of Scope 3 emissions.
Top Scope 3 Categories
Bayer Pharma AG's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Bayer Pharma AG has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
